Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Clinical trials

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Alzheimer's Disease (ad) patients often experience clinically significant agitation, leading to distress, increased healthcare costs and earlier institutionalisation. Current treatments have limited efficacy and significant side effects. Cannabinoid-based therapies, such as the nabiximols oral spray (Sativex®; 1:1 delta-9-tetrahydrocannabinol and cannabidiol), offer potential alternatives. We aimed to explore the feasibility and safety of nabiximols as a potential treatment for agitation in ad. Methods The 'Sativex® for Agitation & Aggression in Alzheimer's Dementia' (STAND) trial was a randomised, double-blind, placebo-controlled, feasibility study conducted in UK care homes. Participants with probable ad and predefined clinically significant agitation were randomised to receive placebo or nabiximols for 4 weeks on an up-titrated schedule, followed by a 4-week observation period. To be considered feasible, we prespecified the following thresholds that needed to be met: randomising 60 participants within 12 months, achieving a ≥ 75% follow-up rate at 4 weeks, maintaining ≥80% adherence to allocation and estimating a minimum effect size (Cohen's d ≥ 0.3) on the Cohen-Mansfield Agitation Inventory. This trial is registered with ISRCTN 7163562. Findings Between October 2021 and June 2022, 53 candidates were assessed; 29 met eligibility criteria and were randomised. No participants withdrew, and adherence was high (100%) and was generally feasible to deliver. The intervention was well tolerated (0 adverse reactions), with no safety concerns reported. Interpretation Despite significant COVID-19 pandemic related challenges, administering nabiximols through oral mucosa to advanced ad patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial to evaluate the potential therapeutic efficacy of nabiximols for agitation in ad.

What this study adds

Evidence grade: Preliminary

The record lists 29 participants. This feasibility trial of nabiximols for agitation in Alzheimer's dementia did not meet its prespecified feasibility thresholds. Its stated limit: Only 29 participants; recruitment target missed; not powered for efficacy; 4-week treatment period.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Albertyn, C. P., Guu, T. W., Chu, P., Creese, B., Young, A., Velayudhan, L., et al. (2025). Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial. Age and Ageing. https://doi.org/10.1093/ageing/afaf149

Vancouver

Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, et al. Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial. Age and Ageing. 2025. doi:10.1093/ageing/afaf149. PMID: 40479610.

BibTeX

@article{albertyn2025-40479610,
  author  = {Albertyn, C. P. and Guu, T. W. and Chu, P. and Creese, B. and Young, A. and Velayudhan, L. and Bhattacharyya, S. and Jafari, H. and Kaur, S. and Kandangwa, P. and others},
  title   = {{Sativex (nabiximols) for the treatment of Agitation \& Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial}},
  journal = {Age and Ageing},
  year    = {2025},
  doi     = {10.1093/ageing/afaf149},
  pmid    = {40479610},
  url     = {https://doi.org/10.1093/ageing/afaf149}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This feasibility trial of nabiximols for agitation in Alzheimer's dementia did not meet its prespecified feasibility thresholds. It was designed to explore feasibility and safety, not to test efficacy.

Study details

Limitations

Only 29 participants; recruitment target missed; not powered for efficacy; 4-week treatment period.

How this study scored 59/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 58 of the 98 points it could be judged on, which is 59 of 100. Total 59 of 100.58 of the 98 points we could judge = 59 of 100

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on free to read, so that was left out: it earned 58 of the 98 points we could judge it on, which is 59 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Age and Ageing)
Journal's citation record 2 / 4 Age and Ageing: journal h-index 231 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial
Strength of evidence 2 / 5 Rated “preliminary” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 29 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 2 / 7 Cited 7 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 3.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Dag Aarsland: h-index 141 (OpenAlex, whole career)
Institution's track record 1 / 3 King's College London: institution h-index 1,348 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40479610)
Free to read — / 2 Access not recorded — left out of this score
Points 58 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 98 points we could judge it on is 59 out of 100.
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Clinical trials from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical trials

See all studies in Clinical trials →